Covered recipient · General Payments record
GERARDO BUESO
Allopathic & Osteopathic Physicians Internal Medicine Endocrinology, Diabetes & Metabolism
A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.
Saved only in this browser. No account or alerts.
General Payments · PY2022 · Entire year
$3,968.53
200 records · 0 disputed
“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”
— Centers for Medicare & Medicaid Services, Open Payments
A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.
These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.
A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.
How these totals are calculated
- This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Methodology & Data — sourcing, labeling, and limitations.
Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗
By nature of payment
PY2022 · entire year · sorted by reported total
| Nature of payment | Amount | Records |
|---|---|---|
| Food and Beverage | $3,746.20 | 195 |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $125.00 | 1 |
| Gift | $59.40 | 1 |
| Education | $37.93 | 3 |
By paying entity
PY2022 · entire year · sorted by reported total
Page 2 of 4; records 51–100 of 200 matching records. This page contains 50 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.
IndustryPayments · General Payments
GERARDO BUESO
NPI 1578658001 · CMS profile ID 253428
Allopathic & Osteopathic Physicians / Internal Medicine / Endocrinology, Diabetes & Metabolism
HOUSTON, TX
A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.
A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.
General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types
Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00
Page 2 of 4; records 51–100 of 200 matching records. This page contains 50 records (maximum 50), not the full filtered export.
Filtered page: https://industrypayments.org/provider/npi-1578658001?year=2022&recipient=provider&page=2#records-h
CMS source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c
Cite these filtered records
The citation includes this program year, filters, data edition, and page of results.
- Plain
- GERARDO BUESO, NPI 1578658001, CMS profile ID 253428. General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 4; records 51–100 of 200 matching records. This page contains 50 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1578658001?year=2022&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c.
- APA 7
- IndustryPayments. (2026). GERARDO BUESO, NPI 1578658001, CMS profile ID 253428. General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 4; records 51–100 of 200 matching records. This page contains 50 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1578658001?year=2022&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c.
- Bluebook
- GERARDO BUESO, NPI 1578658001, CMS profile ID 253428, IndustryPayments, General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 2 of 4; records 51–100 of 200 matching records. This page contains 50 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c. https://industrypayments.org/provider/npi-1578658001?year=2022&recipient=provider&page=2#records-h.
Centers for Medicare & Medicaid Services, Open Payments
Citation formats are provided for reference; check the requirements of your publication.
Payment records · PY2022
Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them
General Payments · PY2022 · Physicians and non-physician practitioners · CMS publication 2026-06-30
200 matching records · $3,968.53 reported total · 0 disputed
Nature of payment: All payment types
Records imported here (UTC).
CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.
Showing records 51–100 of 200.
| Paying entity | Amount | Date | Nature of payment | Dispute status | Publication flags | Published | Record ID | Source |
|---|---|---|---|---|---|---|---|---|
| Abbott Laboratories | $23.83 | 10/04/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 907932765 | CMS |
| Mannkind Corporation | $8.94 | 10/03/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 942752485 | CMS |
| Xeris Pharmaceuticals, Inc. | $14.13 | 10/03/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 946477093 | CMS |
| Amgen Inc. | $12.19 | 09/29/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 939306593 | CMS |
| Amneal Pharmaceuticals LLC | $15.86 | 09/28/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 956575503 | CMS |
| Bayer HealthCare Pharmaceuticals Inc. | $23.30 | 09/27/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 930093415 | CMS |
| AstraZeneca Pharmaceuticals LP | $20.86 | 09/26/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 920255765 | CMS |
| Novo Nordisk Inc | $21.57 | 09/21/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 899616075 | CMS |
| Mannkind Corporation | $14.46 | 09/20/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 942752483 | CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. | $22.11 | 09/15/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 887453881 | CMS |
| Dexcom, Inc. | $15.16 | 09/13/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 957398729 | CMS |
| Novartis Pharmaceuticals Corporation | $1.18 | 09/09/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 893548659 | CMS |
| Xeris Pharmaceuticals, Inc. | $24.48 | 09/09/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 946477089 | CMS |
| Medtronic, Inc. | $19.92 | 09/07/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 933444759 | CMS |
| Novartis Pharmaceuticals Corporation | $16.72 | 09/07/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 893548657 | CMS |
| Abbott Laboratories | $174.33 | 09/01/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 920512871 | CMS |
| Dexcom, Inc. | $22.57 | 08/31/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 957398727 | CMS |
| Mannkind Corporation | $20.51 | 08/30/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 942752481 | CMS |
| Abbott Laboratories | $7.30 | 08/28/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 910335757 | CMS |
| Abbott Laboratories | $2.40 | 08/28/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 910335761 | CMS |
| Lilly USA, LLC | $18.80 | 08/25/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 918018067 | CMS |
| Dexcom, Inc. | $6.78 | 08/24/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 957398725 | CMS |
| AstraZeneca Pharmaceuticals LP | $22.05 | 08/23/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 920227681 | CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. | $13.79 | 08/18/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 887453883 | CMS |
| Lilly USA, LLC | $20.09 | 08/18/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 918010594 | CMS |
| Novartis Pharmaceuticals Corporation | $24.76 | 08/17/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 893548655 | CMS |
| Novo Nordisk Inc | $20.36 | 08/15/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 899138027 | CMS |
| Novo Nordisk Inc | $11.67 | 08/11/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 899296161 | CMS |
| Bayer HealthCare Pharmaceuticals Inc. | $17.23 | 08/09/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 930132841 | CMS |
| Medtronic, Inc. | $13.12 | 08/08/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 933444757 | CMS |
| Xeris Pharmaceuticals, Inc. | $12.33 | 08/04/2022 | Education | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 946477081 | CMS |
| Xeris Pharmaceuticals, Inc. | $20.46 | 08/04/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 946477087 | CMS |
| AstraZeneca Pharmaceuticals LP | $2.50 | 08/03/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 920225113 | CMS |
| Lilly USA, LLC | $13.95 | 07/31/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 918023893 | CMS |
| Bayer HealthCare Pharmaceuticals Inc. | $18.06 | 07/29/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 930113373 | CMS |
| Dexcom, Inc. | $6.54 | 07/29/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 957398723 | CMS |
| Mannkind Corporation | $2.39 | 07/27/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 942752479 | CMS |
| Lilly USA, LLC | $19.09 | 07/26/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 918010598 | CMS |
| Novo Nordisk Inc | $23.54 | 07/21/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 899296555 | CMS |
| Medtronic, Inc. | $23.60 | 07/20/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 933444755 | CMS |
| Novartis Pharmaceuticals Corporation | $20.20 | 07/19/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 893548653 | CMS |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | $12.88 | 07/19/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 960055387 | CMS |
| Corcept Therapeutics | $21.24 | 07/18/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 948777573 | CMS |
| CeQur Corporation | $59.50 | 07/13/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 959112475 | CMS |
| Ipsen Biopharmaceuticals, Inc | $21.45 | 07/13/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 893391661 | CMS |
| Lilly USA, LLC | $29.66 | 07/13/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 917987655 | CMS |
| Amneal Pharmaceuticals LLC | $17.92 | 07/12/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 956575501 | CMS |
| Bayer HealthCare Pharmaceuticals Inc. | $22.87 | 07/11/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 930232633 | CMS |
| Xeris Pharmaceuticals, Inc. | $22.52 | 07/08/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 946477083 | CMS |
| Dexcom, Inc. | $20.44 | 07/05/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 957398721 | CMS |
By program year
All program years on this page · sorted by year
Source & provenance
- Dataset
- CMS Open Payments — General Payments
- Publisher of source data
- Centers for Medicare & Medicaid Services
- CMS publication date
- 2026-06-30
- Program years on this page
- 2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
- Source files
- Dataset page · Bulk file · PY2019 , PY2020 , PY2021 , PY2022 , PY2023 , PY2024 , PY2025
- Generated from
- OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.
Research Payments
One row per program year and role, newest year first · amounts for the two roles are never added together
| Program year | Role | Amount | Records |
|---|---|---|---|
| PY2025 | Principal investigator | $228,935.58 | 27 |
| PY2024 | Principal investigator | $198,266.09 | 7 |
| PY2023 | Recipient | $1,940.54 | 1 |
| PY2023 | Principal investigator | $371,123.80 | 7 |
| PY2022 | Recipient | $3,267.00 | 1 |
| PY2022 | Principal investigator | $34,561.73 | 7 |
| PY2021 | Principal investigator | $62,664.01 | 21 |
| PY2020 | Principal investigator | $147,498.84 | 39 |
| PY2019 | Principal investigator | $103,673.89 | 21 |
Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.
“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”
— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224
Research Payments records · PY2025
Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them
27 records in PY2025
| Role | Paying entity | Amount | Date | Recipient | Study | Dispute status | Published | Record ID |
|---|---|---|---|---|---|---|---|---|
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $93.28 | 12/17/2025 | Non-covered Recipient Entity Houston Methodist-Endocrinology | A simultaneous vs. staggered initiation study of BI 690517 and empagliflozin for SGLT2i treatment-naive participants with CKD | No dispute reported | 06/30/2026 | 1220785139 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $99.90 | 12/17/2025 | Non-covered Recipient Entity Houston Methodist-Endocrinology | A simultaneous vs. staggered initiation study of BI 690517 and empagliflozin for SGLT2i treatment-naive participants with CKD | No dispute reported | 06/30/2026 | 1220785141 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $10,922.00 | 12/10/2025 | Non-covered Recipient Entity Endocrine Associates | A simultaneous vs. staggered initiation study of BI 690517 and empagliflozin for SGLT2i treatment-naive participants with CKD | No dispute reported | 06/30/2026 | 1220815115 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $47.71 | 12/09/2025 | Non-covered Recipient Entity Houston Methodist-Endocrinology | A simultaneous vs. staggered initiation study of BI 690517 and empagliflozin for SGLT2i treatment-naive participants with CKD | No dispute reported | 06/30/2026 | 1220817938 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $70.32 | 12/01/2025 | Non-covered Recipient Entity Houston Methodist-Endocrinology | A simultaneous vs. staggered initiation study of BI 690517 and empagliflozin for SGLT2i treatment-naive participants with CKD | No dispute reported | 06/30/2026 | 1220785129 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $47.41 | 11/26/2025 | Non-covered Recipient Entity Houston Methodist-Endocrinology | A simultaneous vs. staggered initiation study of BI 690517 and empagliflozin for SGLT2i treatment-naive participants with CKD | No dispute reported | 06/30/2026 | 1220817936 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $23.32 | 11/19/2025 | Non-covered Recipient Entity Houston Methodist-Endocrinology | A simultaneous vs. staggered initiation study of BI 690517 and empagliflozin for SGLT2i treatment-naive participants with CKD | No dispute reported | 06/30/2026 | 1220785135 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $139.86 | 11/19/2025 | Non-covered Recipient Entity Houston Methodist-Endocrinology | A simultaneous vs. staggered initiation study of BI 690517 and empagliflozin for SGLT2i treatment-naive participants with CKD | No dispute reported | 06/30/2026 | 1220785137 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $4,269.00 | 11/10/2025 | Non-covered Recipient Entity Endocrine Associates | A simultaneous vs. staggered initiation study of BI 690517 and empagliflozin for SGLT2i treatment-naive participants with CKD | No dispute reported | 06/30/2026 | 1220815113 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $47.41 | 11/10/2025 | Non-covered Recipient Entity Houston Methodist-Endocrinology | A simultaneous vs. staggered initiation study of BI 690517 and empagliflozin for SGLT2i treatment-naive participants with CKD | No dispute reported | 06/30/2026 | 1220817934 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $11.66 | 10/27/2025 | Non-covered Recipient Entity Houston Methodist-Endocrinology | A simultaneous vs. staggered initiation study of BI 690517 and empagliflozin for SGLT2i treatment-naive participants with CKD | No dispute reported | 06/30/2026 | 1220785131 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $19.98 | 10/27/2025 | Non-covered Recipient Entity Houston Methodist-Endocrinology | A simultaneous vs. staggered initiation study of BI 690517 and empagliflozin for SGLT2i treatment-naive participants with CKD | No dispute reported | 06/30/2026 | 1220785133 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $25.84 | 10/21/2025 | Non-covered Recipient Entity Houston Methodist-Endocrinology | A simultaneous vs. staggered initiation study of BI 690517 and empagliflozin for SGLT2i treatment-naive participants with CKD | No dispute reported | 06/30/2026 | 1220817932 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $25.84 | 10/07/2025 | Non-covered Recipient Entity Houston Methodist-Endocrinology | A simultaneous vs. staggered initiation study of BI 690517 and empagliflozin for SGLT2i treatment-naive participants with CKD | No dispute reported | 06/30/2026 | 1220817930 |
| Principal investigator 1 | AstraZeneca Pharmaceuticals LP | $8,500.00 | 09/10/2025 | Non-covered Recipient Entity ENDOCRINE ASSOCIATES | a phase III,randomised,double blind,placebo controlled,event driven study to assess the efficacy,safety and tolerability of baxdrostat in combination with dapagliflozin compared with dapagliflozin alone on renal outcomes and cardiovascular mortality in participants with chronic kidney disease and high blood pressure | No dispute reported | 06/30/2026 | 1185538871 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $7,500.00 | 09/03/2025 | Non-covered Recipient Entity Endocrine Associates | A simultaneous vs. staggered initiation study of BI 690517 and empagliflozin for SGLT2i treatment-naive participants with CKD | No dispute reported | 06/30/2026 | 1220815111 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $46.88 | 09/01/2025 | Non-covered Recipient Entity Houston Methodist-Endocrinology | A simultaneous vs. staggered initiation study of BI 690517 and empagliflozin for SGLT2i treatment-naive participants with CKD | No dispute reported | 06/30/2026 | 1220785121 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $58.30 | 08/26/2025 | Non-covered Recipient Entity Houston Methodist-Endocrinology | A simultaneous vs. staggered initiation study of BI 690517 and empagliflozin for SGLT2i treatment-naive participants with CKD | No dispute reported | 06/30/2026 | 1220785123 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $159.84 | 08/26/2025 | Non-covered Recipient Entity Houston Methodist-Endocrinology | A simultaneous vs. staggered initiation study of BI 690517 and empagliflozin for SGLT2i treatment-naive participants with CKD | No dispute reported | 06/30/2026 | 1220785125 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $36.50 | 08/26/2025 | Non-covered Recipient Entity Houston Methodist-Endocrinology | A simultaneous vs. staggered initiation study of BI 690517 and empagliflozin for SGLT2i treatment-naive participants with CKD | No dispute reported | 06/30/2026 | 1220785127 |
| Principal investigator 1 | Eli Lilly and Company | $22,844.00 | 04/08/2025 | Non-covered Recipient Entity ENDOCRINE ASSOCIATES | A PHASE 3, PARALLEL-DESIGN, OPEN-LABEL, RANDOMIZED CONTROL STUDY TO EVALUATE THE EFFICACY AND SAFETY OF LY3209590 ADMINISTERED WEEKLY USING A FIXED DOSE ESCALATION COMPARED TO INSULIN GLARGINE IN INSULIN-NAIVE ADULTS WITH TYPE 2 DIABETES | No dispute reported | 06/30/2026 | 1187879931 |
| Principal investigator 1 | Eli Lilly and Company | $12,122.00 | 01/28/2025 | Non-covered Recipient Entity ENDOCRINE ASSOCIATES | A PHASE 2, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF VOLENRELAXIN IN ADULTS WITH CHRONIC KIDNEY DISEASE | No dispute reported | 06/30/2026 | 1187883070 |
| Principal investigator 1 | Eli Lilly and Company | $171.00 | 01/26/2025 | Non-covered Recipient Entity ENDOCRINE ASSOCIATES | A PHASE 2, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF VOLENRELAXIN IN ADULTS WITH CHRONIC KIDNEY DISEASE | No dispute reported | 06/30/2026 | 1187879933 |
| Principal investigator 1 | AstraZeneca Pharmaceuticals LP | $16,707.55 | 01/24/2025 | Non-covered Recipient Entity ENDOCRINE ASSOCIATES | A Phase III, Randomised, Multicentre, Double-blind Study to Evaluate the Efficacy, Safety and Tolerability of Zibotentan/Dapagliflozin FDC Compared to Dapagliflozin Alone in Participants with Chronic Kidney Disease and High Proteinuria | No dispute reported | 06/30/2026 | 1185538869 |
| Principal investigator 1 | AstraZeneca Pharmaceuticals LP | $10,528.99 | 01/08/2025 | Non-covered Recipient Entity ENDOCRINE ASSOCIATES | TA description Cardiovascular Renal and Metabolism Indications Chronic Kidney Disease Study status Ongoing Phase descripton Phase 3 Category R&D Sponsored Delivery model Internal | No dispute reported | 06/30/2026 | 1185538867 |
| Principal investigator 1 | AstraZeneca Pharmaceuticals LP | $22,294.34 | 01/08/2025 | Non-covered Recipient Entity ENDOCRINE ASSOCIATES | a phase 3,randomised,double blind,active controlled study to assess the efficacy,safety and tolerability of baxdrostat in combination with dapagliflozin compared with dapagliflozin alone on chronic kidney disease ckd progression in participants with ckd and high blood pressure | No dispute reported | 06/30/2026 | 1185538875 |
| Principal investigator 1 | AstraZeneca Pharmaceuticals LP | $112,122.65 | 01/03/2025 | Non-covered Recipient Entity ENDOCRINE ASSOCIATES | A Phase IIb Randomized Double blind Placebo controlled and Open label Active Comparator Study to Evaluate the Efficacy Safety and Tolerability of AZD5004 in Adults with Type 2 Diabetes Mellitus | No dispute reported | 06/30/2026 | 1185538873 |